Acta Med Iran 2013. 51(6):404-407.

Incidence of Hepatocellular Carcinoma in Patients with Thalassemia Who Had Hepatitis C
Shahla Ansari, Azita Azarkivan, Farideh Halagi


Hepatitis is the infections of a common cause disease among poly transfused patients. Hepatitis C is slowed progression and inducing HCC. This study assessed HCC incidences, the role of iron and possible antitumor activity of chelators in 170 thalassemia patients using deferoxamine (DFO) therapy. They are diagnosed with Hepatitis C due to positive PCR-RNA. They are Treated with IFN. The follow up program including tests every 3 Months and PCR-RNA, AFP and liver US every 6 months. Whenever there was suspicion of liver malignancy, Biopsy was performed. From the total of 170 patients,  59.4% were male, and 40.6% were female. Mean age of thalassemia diagnosis was 2.69±5.403 (1-41) years and mean Age of hepatitis diagnosis was 17.37±7.263 (3-51) years. 92.4 % of Patient’s MT, 0.6 % SS, 2.9% TI. the viral genome was 1a3a. 73.5% of patients had first course of therapy. The frequency of AFP greater than 10 was 5.9%. And the incidence of HCC was 0.6 %(1/170) with a 95% confidence interval. The main risk factor for HCC was HCV infection in TM patients, but it was iron activity in TI patients. Iron chelation with DFO appeared to play a Protective role.


Chelating agents; Cirrhosis; Hepatocellular carcinoma; Hepatitis C virus; Hepatitis B virus; Iron overload; Thalassemia

Full Text: PDF
This article has been downloaded 548 times up to now.


  • There are currently no refbacks.

Acta Medica Iranica, Monthly
ISSN: 0044-6025
(Print), ISSN: 1735-9694 (Electronic), Published by:
Tehran University of Medical Sciences

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.